Please assess the completion status of the following clinical trial:

Trial Title: Assess the Efficacy/Safety of Intravitreal Ranibizumab in Patients With Vision Loss Due to Choroidal Neovascularization.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Diagnosis of active CNV secondary to any causes with the CNV or its sequelae affecting the fovea;~* BCVA must be between ≥ 24 and ≤ 83 letters in the study eye;~* Visual loss in the study eye should mainly be due to the presence of any eligible types of CNV;~Key Exclusion Criteria:~* Women of child-bearing potential;~* Active malignancies;~* History of stroke less than 6 months prior to screening;~* Uncontrolled systemic inflammation or infection;~* Active diabetic retinopathy, active ocular/periocular infectious disease or active severe intra-ocular inflammation;~* CNV- conditions with a high likelihood of spontaneous resolution;~* History of intravitreal treatment with steroids;~* History of laser photocoagulation;~* History of intraocular treatment with any anti-angiogenic drugs.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ranibizumab (Type: EXPERIMENTAL): A 0.5 mg ranibizumab intravitreal injection was given to the study eye at baseline, and then as needed based on evidence of disease activity.
- Sham control (Type: SHAM_COMPARATOR): Sham injection was given to the study eye at baseline, and then treatment was given based on evidence of disease activity. At Month 1, if treatment was needed, sham was administered. At Month 2, participants could switch to open-label ranibizumab on an as needed basis.

Based on this trial design, predict the completion outcome and termination type (if applicable).